Genitourinary Drugs Market analysis research and trends report for 2016-2024

1
Genitourinary Drugs Market trends research and
projections for 2016-2024 Global Market Insights
Inc.
Fuel Cell Market size worth 25.5bn by 2024
2
Regional Analysis of Genitourinary Drugs Market

• U.S. genitourinary drugs market size held a large
  share of the global genitourinary drugs in 2015
  due to robust healthcare infrastructure, growing
  awareness, and technological advancements in the
  development of genitourinary drugs.
• Canada genitourinary drugs market share is
  driving due to the burden of cancer disease in
  the country. As per the Canadian Cancer
  Statistics in 2015, about 196,900 people
  diagnosed with cancer.The data is important to
  focus on prevention efforts, in both primary
  prevention and secondary prevention of cancer,
  and allow more effective treatment of certain
  cancer through earlier detection.
• Europe genitourinary drugs market will witness a
  significant growth over the forecast timeframe.
  It was estimated that over 78 of the new cancer
  medicines that were introduced between 2010 and
  2014 are available within the greater EU. In
  2012, Germanys GDP accounted for over USD
  34,706.8 per capita, driving the industry growth.

3

• Application Analysis of Genitourinary Drugs
  Market
• Prostate cancer contributed to over 25 revenue
  share in 2015. A wide range of therapeutics, such
  as radiopharmaceuticals, immunotherapy
  medication, and anti-neoplastic agents, available
  to treat prostate cancer will drive this
  segments growth. According to National Cancer
  Institute (NCI), the total number of new prostate
  cancer cases between 2009 to 2013 were 129.4 per
  100,000 men every year.
• Urinary Tract Infections (UTIs) affect more than
  150 million people every year worldwide,
  resulting in direct healthcare expenses of over
  USD 6 billion. Around 2.4 percent of women and
  men will be detected with bladder cancer at some
  point during their lifetime.

4
Competitive Market Share of Genitourinary Drugs
Market

• Companies are focusing on the implementation of
  strategies including mergers acquisitions, new
  product development, and regional expansion. In
  October 2016, the U.S. FDA approved a
  supplemental Biologics License Application (sBLA)
  of Bristol-Myers Squibb, to enlarge the practice
  of Opdivo (nivolumab) to treat patients suffering
  from an advanced form of bladder cancer.
  Similarly, in June 2016, the U.S. National
  Surgical Adjuvant Breast and Bowel Project
  (NSABP) and Bayer, collaborated on a new Phase
  III trial to study Stivarga (regorafenib) tablets
  as an adjuvant therapy in colon cancer. Growing
  geographical presence of the industry players is
  expected to raise the awareness levels regarding
  treatment options for genitourinary diseases
  among the patients and the doctors.

5

Browse Full Market Research Report On
Genitourinary Drugs Market _at_ https//goo.gl/X5cCaf
Request for an in-depth table of contents for
this report _at_ https//www.gminsights.com/request-t
oc/upcoming/1382 Gaming Console Market
6
Stay In Touch Website www.gminsights.com Soci
al Media